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PQUARTERLY FOCUS ISSUE: HEART FAILURE
Assessment of the Potential Heart Donor
A Role for Biomarkers?
Vamsidhar B. Dronavalli, MB,*†‡ Nicholas R. Banner, MB,§ Robert S. Bonser, MD*†
Birmingham and Middlesex, United Kingdom
Demand for donor hearts exceeds supply, and a significant number of patients die while awaiting transplanta-
tion. Within the pool of currently unused potential donor hearts, a proportion may be suitable for transplantation
but are declined due to anticipated poor function. Despite current assessment methods, in some donor hearts
accepted for transplantation early graft failure develops in the recipient. Current methods of assessment are
inadequate, and there is a potential for biomarkers to improve identification of satisfactory hearts for transplan-
tation or hearts destined to fail in the recipient. Biomarkers are routinely used to diagnose and risk-stratify myo-
cardial infarction, acute coronary syndromes, and heart failure. Some of these might facilitate donor heart as-
sessment. Cardiac troponins, cytokines, inflammatory markers, natriuretic peptides, and intracellular proteins
may each have discriminant value. This review details the current status of biomarkers in the assessment of
donor hearts. (J Am Coll Cardiol 2010;56:352–61) © 2010 by the American College of Cardiology Foundation




























teart transplantation (HTx) provides a substantial survival
dvantage in selected patients with advanced heart failure (HF)
1), transforming a very limited prognosis into a 1-year survival
ate of 80% and a 5-year survival of 65% (2).
Many patients on a list for HTx die while awaiting a
atisfactory donor heart. The shortfall in donor heart supply
bliges HTx centers to consider older, so-called marginal
onor hearts with less assured post-transplantation outcomes
1). Each time a donor heart is considered for transplantation,
he candidate and his or her physicians must weigh the balance
etween the continued risks of medical therapy and the risk of
Tx. The most significant early risk after HTx is the primary
ysfunction of the donor heart. Although treatable in a
inority by mechanical circulatory support, in the majority,
uch dysfunction is manifest as primary graft failure leading to
eath or dysfunction with secondary organ failure, which may
e lethal. Despite the great need for donor organs, the
roportion of hearts ultimately retrieved from the initial pool of
onor hearts is low (2).
Donor hearts mainly arise from victims of trauma, intracra-
ial hemorrhage, intracranial primary tumors, and a small
umber of miscellaneous causes. The cause of death per se does
ot affect post-transplantation survival or likelihood of being
sed as a donor heart if adjusted for age. As traumatic brain
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010, accepted February 16, 2010.eath is declining, the fraction of brain death from intracranial
emorrhage is increasing, along with an increase in the mean
ge of the eligible donor pool, increasing from 23 years in 1983
o 30 years in 2005 to 2007. Although the mean age remains
nly 30 years, the proportion of donors older than 50 years now
akes up 12% of the donor population, and this underscores
he importance of careful donor assessment (2–4). Although
lder donor hearts can be safely transplanted, increasing donor
ge worsens post-transplantation prognosis at 1 and 5 years (2)
nd is associated with an increasing prevalence of donor
oronary artery disease.
The best way to assess the donor heart is an issue of
ebate. Most protocols of assessment are based, at least in
art, on a consensus report that highlighted an algorithm of
ssessment and management commencing with an initial
chocardiogram dichotomizing donors based on a threshold
eft ventricular ejection fraction (LVEF) of 45% (5). In
onors with an LVEF 45%, progression to retrieval for
ransplantation was recommended, whereas donors with an
VEF 45% were subjected to hormonal resuscitation and
emodynamic management based on pulmonary artery
atheter assessment of cardiac index, filling pressures, and
ascular resistance (Fig. 1) (6).
If echocardiography is the initial assessment investiga-
ion, echocardiographically detected left ventricular (LV)
ystolic dysfunction in the absence of a history of heart
isease is the single most common cause for nontransplan-
ation of an organ (7). However, ventricular dysfunction
ay be transient (8,9), and arbitrary thresholds of LV
unction may exclude hearts that could be resuscitated to
ransplantable status. This exclusion is compounded by the
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July 27, 2010:352–61 Assessment of the Potential Heart Donorlthough defining the hemodynamic status of the donor
eart and facilitating management of ventricular filling and
fterload (3,10), is usually reserved for the heart donor
lready provisionally accepted for transplantation and attended
y a retrieving team. However, the achievement of defined
emodynamic performance criteria of mean arterial pressure
60 mm Hg, central venous and pulmonary capillary wedge
ressures12 mm Hg with cardiac indices2.4 l·min1m2
nd normal vascular resistance is associated with very satisfac-
ory outcomes and appears to be the cornerstone of the final
ssessment of donor pre-retrieval (8,11).
As many as two-thirds of hearts offered for transplanta-
ion are rejected as being unsuitable or likely to fail if
ransplanted. This rejection occurs before detailed organ
nspection, and in 90% of cases is based on an anticipation
f poor donor organ function in the recipient. The clinical
ecision to discount these organs is based on data regarding
lood pressure, electrocardiographic change, periods of
ypotension, periods of cardiopulmonary resuscitation, drug
istory, history of hypertension, and the need for inotropic
upport (12). However, none of these factors alone neces-
arily precludes successful HTx. Thus, there is a pool of
nused hearts, for which permission for heart donation has
een granted, from which additional transplants could be
enerated if we could be more confident of their post-
ransplantation performance.
Furthermore, between 10% and 50% of attempted re-
rievals are aborted because of donor heart malfunction
etected on inspection. This cohort raises the matter of
xpense, wasted man hours, and the potential to jeopardize
ther cardiac surgical activity in units where transplantations
nd other procedures share the same operating room facilities
nd staffing. These issues reaffirm the requirement for im-
roved evaluation of the donor to define those hearts in which
atisfactory function is maintained and achievable and should
e subjected to further assessment and direct inspection.
he Brainstem-Dead Heart
eating Multiorgan Donor Physiology
he process of brain death leads to intensive sympathetic
ervous system activity followed by a vasoparesis (13–15). In
he heart, this intense catecholamine release is believed to
ause at least transient myocardial ischemia and injury. Such
njury might be exacerbated by changes in endocrine ho-
eostasis, metabolism, and the development of a proin-
ammatory state.
In patients with subarachnoid hemorrhage (SAH),
lasma catecholamine levels have been demonstrated to
eflect the severity of the neurological insult acting as a
hysiological marker of patient outcome in both the acute
nd chronic phases of traumatic brain injury (16).
This intensive sympathetic activity and catecholamine
elease associated with brain death (17,18) may result in
yocardial ischemia and injury (9,19–22), calcium over- Soad (21,23,24), a possible reduc-
ion in high-energy phosphates
18,25–27), beta-adrenoreceptor
esensitization (28–30), endothe-
ial damage (22,25,27,31,32), and
ltered gene expression (33). Ele-
ated cytosolic calcium levels are
elieved to activate enzymes such
s lipase, protease, endonuclease,
nd nitric oxide synthase (22), dis-
upting high-energy phosphate
roduction and resulting in oxygen
ree radical generation and further
ontributing to organ damage.
he recovery of cardiac function is
urther limited by a decrease in the
oronary reserve (34).
ndocrine Changes
euthyroid sick state may occur
ogether with hypothalamic-pituitary failure, resulting in neu-
ogenic diabetes insipidus (17) with an associated decrease in
asopressin. Further decreased thyroid hormone (especially
riiodothyronine [T3]), insulin, and cortisol levels are seen (35).
ituitary failure produces abnormal temperature homeostasis,
nd eventually a catecholamine-deficient vasoparetic state oc-
urs. All these phenomena may further affect cardiac function
13,21,36–44). Brain death is also followed by release of the
roinflammatory cytokines, tumor necrosis factor (TNF)-,
nd interleukin (IL)-1 and -6 (45,46), which may exacerbate
rgan injury.
The impact of these biochemical and endocrine changes
n the recipient outcome is unclear. A low T3 in itself does
ot portend impaired ventricular function or a failure to
espond to hemodynamic management (11,47). Although
3 administration has been recommended by some groups
48), the relevance of this remains a subject of debate and
ontroversy (3,49,50).
lectrocardiographic Assessment
n the Heart Donor
large number of donors (47% to 100%) have abnormali-
ies on the electrocardiogram (51,52), but no specific elec-
rocardiographic abnormality has been found to be a sensi-
ive indicator of donor heart outcome. In SAH,
lectrocardiographic changes similar to those of myocardial
nfarction have been reported (53–56), which correlate with
he extent of neurological injury and higher mortality
57,58). In SAH, T-wave inversion or severe QTc prolon-
ation is highly predictive of concomitant LV dysfunction,
yocardial injury, and increased mortality (59–61). Further
tudies have associated electrocardiographic changes in
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Assessment of the Potential Heart Donor July 27, 2010:352–61nd hypokalemia have been demonstrated as independent
isk factors for prolonged QTc (63). These reports and
thers showing a potential association between the severity
f SAH-related neurological deficit and cardiopulmonary
ysfunction (60,64) give rise to the suggestion that the
lectrocardiography may potentially be utilized to assess the
rainstem-dead donor. Although of promise in identifying a
igh-risk donor, electrocardiography as a solitary investiga-
ion is unlikely to define a heart that is suitable or unsuitable
or transplantation unless definitive pathological abnormal-
ties (Q waves, left bundle branch block) are identified.
chocardiographic Assessment
f the Donor Heart
normal LVEF in the potential donor is predictive of heart
se and satisfactory recipient outcome (8). Echocardio-
raphic myocardial dysfunction is, however, common, and
ccurs in 10% to 42% of donor hearts (65–67). The
mpairment is reported as severe in as many as 20% (68),
nd LV impairment constitutes the main reason for hearts
Figure 1 The Recommended Heart Donor Management Algorith
Incorporated Into the United Network for Organ Sharin
CI  cardiac index; CVP  central venous pressure; echo  echocardiography; Hc
left ventricular hypertrophy; MAP  mean arterial pressure; PAFC  pulmonary art
SVR  systemic vascular resistance; T3  triiodothyronine. Reproduced with permeing declined for transplantation (3,69,70). However, the pchocardiographic dysfunction of the donor heart can im-
rove either within the donor or within the recipient. This
mprovement includes resolution of subdued LV function,
egional wall motion abnormalities, and ventricular hyper-
rophy (2,68,71,72). Thus, the utility of echocardiography
n donor heart assessment has been questioned because
dherence to strict limits of function may inappropriately
xclude hearts that could be used successfully. The presence
f LV hypertrophy may also deter the use of donor hearts
73). However, recent studies demonstrated that hearts with
ild to moderate left ventricular hypertrophy have similar
hort- and longer-term outcomes provided other risk factors
re simultaneously considered (e.g., ischemic time) (74).
here are few data comparing echocardiographic findings
nd pulmonary artery catheter measurements, but recent
eports suggest that many hearts with adverse initial hemo-
ynamics or echocardiography can be successfully managed
o a state where transplantation is possible (8). Recent
vidence suggests that dobutamine stress echocardiography
ay be useful in assessing hearts with echocardiographic
bnormalities and may alert the retrieval team to the
itical Pathway
matocrit; LV  left ventricular; LVEF  left ventricular ejection fraction; LVH 
ation catheter; PCWP  pulmonary capillary wedge pressure; sat  saturation;
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July 27, 2010:352–61 Assessment of the Potential Heart DonorThus, a significant number of hearts are rejected on
imited clinical and echocardiographic criteria. At least
ome of these should progress to direct assessment and
nvasive monitoring, and some could probably be used
uccessfully if preliminary assessments could be more pre-
ictive of a successful retrieval and transplantation. The
bjective, therefore, is to identify markers that indicate that
earts that are likely to have good function or be manipu-
atable to satisfactory hemodynamic status and transplanta-
ion suitability. This could increase the yield of hearts from
he existing donor pool, increase transplantation rates, and
mprove recipient outcomes.
he Potential for Biomarker
ssessment of the Donor Heart
he demographic, clinical, electrocardiographic, and echo-
ardiographic features of the potential heart donor are each
isappointingly insensitive or nonspecific in determining
hether an individual heart should be used or rejected for
ransplantation. Apart from donor age and ischemic time,
here are few donor-related risk factors that are predictive of
oor outcome. Despite this, there is evidence that primary
ransplant organ dysfunction in hearts, lung, and kidneys
ay all occur when organs are from a single donor (76). This
uggests that as-yet unidentified donor factors may be impor-
ant both in terms of assessing organ usability and predicting
raft failure in the recipient. Each of the phenomena that may
ead to or increase cardiomyocyte injury in association with
rain death lends itself to biochemical assessment. Therefore, it
ay be possible to use biomarkers to predict donor heart
ysfunction or suitability for transplantation.
he Search for a Biomarker
o Assess the Donor Heart
heart donor biomarker should have a high sensitivity and
pecificity to predict which hearts can have a satisfactory
emodynamic outcome in a recipient and conversely to
dentify those hearts that should not be transplanted (i.e.,
redicting nonuse or primary graft failure in the recipient).
he added dimensions of donor and recipient variables and
heir interaction add to the complexity of the assessment use of
arkers in this situation. Nevertheless, the likely biochemical
bnormalities that occur after brain death may in fact yield
mportant predictive information, allowing risk stratification of
he potential heart donor just as can occur in myocardial
nfarction, acute coronary syndromes, and HF (77,78).
ardiac troponins. The cardiac-specific troponins cTnI
nd cTnT have replaced creatine kinase-myocardial bound
raction as the preferred biomarkers in patients with myo-
ardial infarction (77) and may have an important role in the
ssessment of the cardiac donor. Cardiac troponin elevation
s prevalent in patients with SAH and in this setting is
ssociated with increased LV dysfunction, pulmonary
dema, hypotension requiring drug support, and worse
atient outcome (79). In potential heart donors, a degree of tTnI elevation appears to be universally present and 37%
ave cTnI levels 1 g/l (3). Higher levels have been
bserved after intracranial hemorrhage rather than trauma
s a cause of brain death (80). Higher troponin levels have
een noted in donor hearts with a worse LVEF or hemo-
ynamic function (3,81–83). As expected, levels of cTnT
nd cTnI show a strong correlation.
The phenomenon of troponin elevation and cardiac
ysfunction in the donor may be transient, suggesting
ltered sarcolemmal integrity rather than myocyte necrosis.
n SAH, high troponin levels are associated with reversible
ardiac dysfunction (84), and similar reversibility of dys-
unction has been observed in heart donors (3,85).
The time from coning at which troponins are measured
ppears to influence their levels. Higher levels are recorded
loser to the coning event, and as time from coning
ncreases, troponin levels fall and cardiac function improves
3). This may suggest a reversible stunning phenomenon
nd has implications for donor management and procure-
ent services.
Thus, troponin levels may act as a surrogate marker of
entricular function in the donor, but what happens when
he heart from a donor with elevated troponin is trans-
lanted? The evidence here is mixed. Andersen et al. (82)
eported that higher troponin levels were associated with an
ncreased need for inotropes in the recipient, and other
tudies found that donor troponin may be predictive of early
raft failure in the recipient (83,86). This finding has been
orroborated in the pediatric population in which donor sera
TnI concentration has been shown to be strongly related to
he subsequent presence of fatal primary graft failure in
nfants (86).
In contrast, Khush et al. (87) demonstrated that a
oderately elevated cTnI in the donor was not associated
ith the need for mechanical support post-operatively or
urvival at 30 days or 1 year in the recipient. However, there
as a tendency for a longer in hospital stay in recipients
hose hearts were from donors with higher cTnI.
The incidence and severity of cardiac rejection in the
ecipient have also been demonstrated to be associated with
n elevated donor cTnT (88). Thus, from these studies, it is
pparent that troponin levels in the donor may relate to the
unction within the recipient, the outcome of the donor
eart, and the outcome both early and mid-term in the
ecipient. A discriminatory cutoff in troponin levels that
uggests that an individual donor heart should not be used
emains undefined. Although cTnI levels 1 g/l may be
redictive of subnormal donor heart function (3), certain
earts with troponins above these criteria have been associ-
ted with successful transplantation. cTnT levels also pre-
ict donor heart function (89) (Fig. 2). One flag in the field
s a cTnT0.1 g/l or a cTnI1.6 g/l, each of which has
een reported to have a high sensitivity and specificity for
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Assessment of the Potential Heart Donor July 27, 2010:352–61NF-
he up-regulation of proinflammatory cytokines seen in HF
lso occurs after brain death (67,90). The most studied
ytokine is TNF-, which is synthesized by nucleated
yocardial cells in response to cardiac stress including
yocardial infarction and LV pressure or volume overload
32,91,92). Neither TNF mRNA or TNF protein is con-
titutively expressed in the nonfailing heart but are uni-
ormly expressed in the failing myocardium (93,94). When
dministered exogenously in experimental models, TNF
rovokes cardiomyocyte hypertrophy and triggers apoptosis.
t also blunts responsiveness to adrenoreceptor agonists and
mpairs contractile function (95) via a number of possible
echanisms (29,96,97). Elevated levels of TNF- are seen
n and may antedate HF. TNF- correlates with disease
everity and can predict mortality, independent of age, sex,
r HF etiology (98,99). The relationship between elevated
NF- and mortality is believed to be a direct toxic effect
ather than an epiphenomenon (32,67).
In heart donors, myocardial expression of TNF-mRNA
nd serum TNF levels may be increased (45,46) (Fig. 3).
levation occurs in nearly 30% of potential cardiac donors,
nd higher levels are observed in donors with marginal heart
unction (46). The greatest increase is in donor hearts
ejected due to poor function (100). In these donors,
NF- levels exceed those seen in advanced HF.
L-6
he circulating level of another cardiotoxic cytokine, IL-6,
ay also be important. In HF, increased IL-6 has been
emonstrated to be associated with decreased cardiac func-
Figure 2
Correlation Between LVEF Area
and Circulating Cardiac Troponin T
Concentration in Brain-Dead Patients
n  100;   0.59, p  0.0001. This relationship was best fitted using an
exponential curve. Reprinted with permission from Riou et al. (89). LVEF  left
ventricular ejection fraction.ional status, low ejection fraction, high right atrial pressure,nd poor prognosis. Significant elevation of IL-6 occurs in
robably all heart donors (3), and some studies have shown
t to be higher in both the myocardium and serum of donor
earts rejected for transplantation due to poor heart func-
ion (Fig. 3) (46). Expression of IL-6 and its receptor
omponents in donor hearts is comparable to that observed
n advanced HF (101).
rocalcitonin
rocalcitonin (PCT) is a precursor of the hormone calcito-
in and is systemically released in sepsis. Increased PCT
evels have been found in 87% of potential heart donors, and
igher levels correlate with deteriorating indices of heart
unction; LVEF, right ventricular ejection fraction, and
ardiac index (3). The serum level above which PCT
ppears to be associated with adverse heart function and
ecipient outcome is approximately 2 ng/ml. This cutoff
easonably discriminates between those hearts matching or
ot matching functional suitability criteria for transplanta-
ion after donor management with a sensitivity of 88%, but
poor specificity (Fig. 4) (3,102). PCT levels2 ng/ml may
lso be a predictor of early graft dysfunction after transplan-
ation. Wagner et al. (103) investigated 81 consecutive
Figure 3 TNF- and IL-6 Expression in Donor Hearts
(A) Myocardial tumor necrosis factor (TNF)- expression in myocardium from
donors with hearts rejected for transplantation is significantly higher than that
in hearts suitable for transplantation or those with advanced heart failure.
(B) Interleukin (IL)-6 expression in the donor heart. IL-6 expression is higher in
donor hearts rejected for transplantation. Reproduced with permission from
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July 27, 2010:352–61 Assessment of the Potential Heart Donorrain-dead heart donors reporting a mortality from early
raft failure of 10%. Higher donor PCT levels were noted,
nd a PCT level 2 ng/ml predicted early graft failure–
elated mortality (103).
Interestingly, donor PCT levels appear to correlate
trongly with other potential biomarkers. In 79 potential
eart donors investigated, PCT levels correlated with
iomarkers involving different noninflammatory patterns of
njury (cTnI: r  0.346, p  0.005; cTnT: r  0.387, p 
.0014; N-terminal pro–B-type natriuretic peptide [NT-
roBNP]: r  0.368, p  0.0025; and heart type fatty acid
inding protein: r  0.45, p  0.001) (V.B. Dronavalli et
l., unpublished observations, 2009). Potapov et al. (82)
ombined PCT and cTnT levels as potential predictors of
arly graft failure in 92 donor hearts, of which 14 had early
raft failure. PCT 2 ng/ml together with elevated cTnT
ad a high sensitivity in identifying hearts associated with
arly graft dysfunction (82).
-Type Natriuretic Peptide (BNP)
nd NT-proBNP
NP and NT-proBNP are released from ventricular myo-
ardium in response to increased wall stress (36,104,105).
NP is produced as a prohormone that is cleaved toward
he N-terminal to produce BNP and the terminal portion
T-proBNP. Both aid the diagnostic and prognostic as-
essment of HF and myocardial infarction and correlate
ith ventricular dilation, remodeling, dysfunction, HF de-
Figure 4 Predictive Value of Procalcitonin in
Identifying Adverse Donor Heart Function
Receiver-operator characteristic curve demonstrating the relationship between
sensitivity and 1  specificity in determining the predictive value of procalcito-
nin 2 ng/ml for identifying adverse heart function. Reproduced with permis-
sion from Venkateswaran et al. (102).elopment, and death after acute myocardial infarction s78,105,106) and acute coronary syndrome (77,78,107,108).
n addition, elevated BNP is predictive of diastolic dysfunc-
ion even in the presence of normal systolic function
109,110).
In SAH, BNP levels are elevated in accordance with
eurological severity and the presence of cardiac dysfunction
3,111,112). In the brain-dead potential heart donor, BNP
evels are higher in those hearts with worse echocardio-
raphic function and those unsuitable for transplantation
113). We recently studied NT-proBNP levels in poten-
ial heart donors and found that levels closely correlate
ith indices of cardiac function, both hemodynamic and
chocardiographic, and are also predictive of which hearts
chieve hemodynamic suitability criteria (114). The likely
echanism of cardiac dysfunction after severe brain
njury or brainstem death is excessive myocardial cate-
holamine release leading to cardiac ischemia (18). Even
ransient ischemia results in an immediate increase in
NP, and the magnitude of the increase is proportional
o the severity of the ischemia The BNP prohormone is
robably synthesized in ventricular myocytes in response
o the cardiac wall stress and pressure overload that occur
t the time of cerebral injury or coning. After SAH, BNP
evels are elevated in plasma but not in cerebrospinal
uid. This suggests a nonbrain source of BNP, and the
eart is a likely source (114).
Thus, as a marker of myocardial stress, BNP or its
nalogues represents a further possible biomarker tool in the
ssessment of the heart donor.
MARCAL1
MARCAL1 (SWI/SNF-related, matrix-associated, actin-
ependant regulator of chromatin subfamily A-like 1) is an
ntracellular protein that acts as a DNA-dependent ATPase
nvolved in transcription, DNA repair, and chromatin
ynamics (115). Donor serum levels of SMARCAL1 were
ecently demonstrated to be elevated in donors whose grafts
evelop primary graft dysfunction. Ahrinejad et al. (116)
emonstrated in a cohort of 336 heart donors that
MARCAL1 levels were significant predictors of 3-month,
-year, and 5-year survival and primary graft dysfunction.
sing a donor serum cutoff of 1.25 ng/ml, they demon-
trated 96% sensitivity and 88% specificity for predicting
rimary graft dysfunction, with a corresponding positive
redictive and negative predictive values of 83% and 97%,
espectively, identifying a potential role of SMARCAL1 in
rgan selection even before the surgical retrieval. Although
he serum analysis methodology for SMARCAL1 is avail-
ble commercially, the main limitations for clinical use
ould be the duration taken for serum analysis. In addition,
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Assessment of the Potential Heart Donor July 27, 2010:352–61redictors in Combination
one of these potential biomarkers fully discriminate be-
ween donor hearts that should or should not be used for
ransplantation. Interestingly, they describe different modes
f myocyte injury and stress and the proinflammatory
nvironment and have therefore the potential to be used in
ombination to aid donor heart assessment. Preliminary
ndings have demonstrated that levels of NT-proBNP,
roponins, and PCT correlate significantly, and thus multi-
arker assessment has the potential to act as an important
ssessment tool. There are a few studies addressing com-
ined variables. In 1 study, the combination of troponin and
NP assessment increased the discrimination of hearts
estined to have early graft failure (117), whereas another
ummary of Studies Investigating Trends of Biomarkers in the HeaTable 1 Summary of Studies Investigating Trends of Biomarker
Biomarker Ref. #/Year Groups (n)
cTnT 82/2003 Donor hearts with good recipient
function (77)
Donor hearts with early graft
failure (14)
Prosp





89/1995 Donor hearts with severely decreased
LVEF (14)
Donor hearts with moderately
decreased LVEF (25)
Donor hearts with normal LVEF (61)
Prosp
cTnl 86/1994 Pediatric heart donors
cTnI 3 ng/ml (8)
cTnI 3 ng/ml (11)
Prosp
83/2001 Good donor graft (68)
Grafts with impaired function (11)
Grafts not accepted for
transplantation (39)
Prosp
TNF- 46/2000 Donor hearts used (31)
Donor hearts not used (15)
Prosp
IL-6 46/2000 Donor hearts used (31)
Donor hearts not used (15)
Prosp
PCT 103/2001 Donor hearts when recipient died
within 30 days (8)
All other donors (71)
Prosp
BNP/NT-proBNP 114/2010 Donors with hemodynamics suitable
for donation (40)
Donor hearts hemodynamically
unsuitable for donation (39)
Prosp
SMARCAL1 116/2009 Heart donors (336) ProspNP  B-type natriuretic peptide; cTn  cardiac troponin; echo  echocardiography; IL  interleukin; L
R  odds ratio; PCT  procalcitonin; SMARCAL1  SWI/SNF-related, matrix-associated, actindependanuggested added discriminant value by adding troponin and
CT (82). In the United Kingdom, a large study (approx-
mately 1,200 potential heart donors) is currently under way
o ascertain whether such biomarkers can predict the usabil-
ty of donor hearts and to explore whether certain hearts
urrently rejected for transplantation on limited clinical
nformation may have a biomarker signature that suggests
uitability. Overall, biomarker assessment to assess whether
earts should be used for transplantation and the develop-
ent of models to predict early graft failure in the recipient
how significant promise and have the potential to widen
he pool of donors available for transplantation, to direct
onor management, and to improve outcomes in the recip-
ent (Table 1).
norhe Heart Donor
of Study End Points Conclusion
, observational 64% sensitivity, 97% specificity;
OR: 68.4 (p  0.0001) for
development of early graft failure
after heart transplantation
, observational Grade and duration to
first rejection,
1-yr follow-up
Significant linear correlation between
donor TnT and grade of rejection
(r  0.943, p  0.0001)
, observational LVEF in donor cTnT significantly higher in group
with severe decrease in LVEF
(p  0.01).
cTnT 0.5 g/l had sensitivity  1,
specificity  0.84 for predicting
severe decrease in LVEF
, observational Primary graft failure,
recipient LVEF,
mortality 12 months
Relationship between high cTnI and
graft failure (p  0.005)
, observational Acute graft failure cTnI 1.6 g/l 94% specificity as a
predictor of early graft failure;
OR for development of graft
failure: 42.7
, observational Used/unused donor
heart
Serum TNF- higher in unused hearts
compared with used hearts
(p  0.05)
, observational Used/unused donor
heart
IL-6 level significantly higher in both
groups compared with normal
, observational Mortality within 30 days
after transplantation
as a result of early
graft dysfunction
PCT 2 ng/ml; 50% sensitivity and
98% specificity for predicting early






A high plasma NT-proBNP was
associated with poor cardiac
function. Some of the parameters
assessed were pulmonary
capillary wedge pressure, cardiac
power output index, LVEF, and
specific echo parameters
3-month, 1-yr, and 5-yr
survival and primary
graft dysfunction
Using a donor serum cutoff 1.25
ng/ml, they demonstrated 96%
sensitivity and 88% specificity for
predicting primary graft
dysfunction, with corresponding
positive predictive and negative
predictive values of 83% and 97%,











ectiveVEF  left ventricular ejection fraction; NT-proBNP  N-terminal pro–B-type natriuretic peptide;
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